Professor, Michigan State University
Director, Energy Biosciences Inst., UC Berkeley
Principal Researcher, Microsoft Research Silicon Valley Laboratory
Managing Partner, Triathalon Medical Ventures Fund II
Chair, Dept. of Cellular and Molecular Pharmacology, UCSF
Professor of Molecular Biology, Rockefeller University
President and CEO, Complete Genomics
Co-Founder and Chairman, Cleantech San Diego
|
On the heels of Renaissance Venture Capital announcing earlier this month that it had its first close of $60 million on its second fund, the Michigan Venture Capital Association (MCVA) released its annual report on the state of Michigan’s venture ecosystem.... Read more »
San Diego Xconomist Evan Snyder has been called a “stem cell revolutionary” and is regarded as a father in the field of stem cell research. When we talked in his office at San Diego’s Sanford-Burnham Medical Research Institute, he told me he... Read more »
When the X Prize Foundation’s Peter Diamandis took the stage in San Diego this morning at the Wireless-Life Sciences Alliance (WLSA) annual convergence summit, he said it was the perfect audience for announcing the foundation’s newest competition—the “Nokia Sensing X Challenge.”
The challenge,... Read more »
It’s been a busy week for startup funding, with Obalon Therapeutics, Aperio Technologies, Topera, and Ivera Medical closing on financing deals. We’ve also got drug development news from Ocera Therapeutics and MediciNova.
—Japan’s Takeda Pharmaceutical said it’s closing its center of excellence in... Read more »
On June 1, cancer scientists and drugmakers will flock to Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO). The gathering is so prominent that many pharmaceutical companies hold off on releasing data from their clinical trials... Read more »
At first glance, the $1.1 million financing announced by Halo Therapeutics on Tuesday looked like your average case of a biotech startup scraping together enough money to get its early-stage compound into pivotal human trials. But this funding was anything but average.... Read more »
It was clear that San Diego’s MediciNova (NASDAQ: MNOV) had a lot riding on the outcome of a mid-stage trial of the company’s lead drug candidate, bedoradrine sulfate. As I reported recently, MediciNova has been developing the compound to treat acute asthma attacks... Read more »
Managing Director, GlobalSmartEnergy
Managing Director, DaggerBoard Advisors
Partner, Advanced Technology Ventures
Research Fellow, MIT Sloan School and Entrepreneurship Center
Prof. Dept. of Medicine/Hematology, Univ. of Washington
San Francisco · 6/7/12
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
